Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ionis Pharmaceuticals

27.09
-1.4300-5.01%
Post-market: 27.090.00000.00%19:20 EDT
Volume:2.29M
Turnover:62.85M
Market Cap:4.31B
PE:-8.92
High:28.50
Open:28.10
Low:26.88
Close:28.52
Loading ...

Ionis Pharmaceuticals management to meet with Oppenheimer

TIPRANKS
·
05 Apr

Ionis to host expert panel discussion on sHTG

Business Wire
·
03 Apr

Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease

Dow Jones
·
02 Apr

Ionis Pharmaceuticals Initiated at Neutral by Redburn Atlantic

Dow Jones
·
31 Mar

Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target

MT Newswires Live
·
31 Mar

Ionis to present at upcoming investor conferences

Business Wire
·
31 Mar

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?

Zacks
·
28 Mar

IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi

Zacks
·
27 Mar

Ionis Partners With Sobi to Commercialize Familial Chylomicronemia Syndrome Treatment Outside US

MT Newswires Live
·
26 Mar

BRIEF-Ionis Expands Partnership With SOBI To Include Olezarsen Commercialization Outside The U.S.

Reuters
·
26 Mar

Ionis Expands Partnership With Sobi to Include Olezarsen Commercialization Outside the U.S.

THOMSON REUTERS
·
26 Mar

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

Business Wire
·
26 Mar

Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey
·
26 Mar

Ionis Pharmaceuticals Is Maintained at Neutral by JP Morgan

Dow Jones
·
24 Mar

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Simply Wall St.
·
24 Mar

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy

Reuters
·
24 Mar

Ionis Pharmaceuticals: Strategic Partnerships and Financial Flexibility Drive Buy Rating

TIPRANKS
·
17 Mar

Ionis Pharmaceuticals Inc : Leerink Partners Raises Target Price to $55 From $52

THOMSON REUTERS
·
13 Mar

BRIEF-Ionis And Ono Announce Global License Agreement For Sapablursen In Polycythemia Vera

Reuters
·
12 Mar

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

Business Wire
·
12 Mar